$-0.32 EPS Expected for Aralez Pharmaceuticals Inc. (ARZ); Last Week MacroGenics, Inc. (MGNX) Analysts

April 25, 2018 - By Adrian Erickson

Among 11 analysts covering MacroGenics (NASDAQ:MGNX), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. MacroGenics had 25 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of MacroGenics, Inc. (NASDAQ:MGNX) has “Neutral” rating given on Thursday, September 17 by Citigroup. The rating was maintained by BTIG Research on Friday, January 19 with “Buy”. The stock has “Buy” rating by SunTrust on Tuesday, January 23. As per Monday, August 7, the company rating was maintained by Morgan Stanley. The rating was maintained by SunTrust on Friday, September 1 with “Buy”. The firm earned “Buy” rating on Monday, August 10 by Zacks. The firm has “Equal-Weight” rating by Morgan Stanley given on Thursday, February 25. Morgan Stanley maintained the shares of MGNX in report on Wednesday, March 14 with “Equal-Weight” rating. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, August 6. On Tuesday, December 20 the stock rating was initiated by SunTrust with “Buy”. See MacroGenics, Inc. (NASDAQ:MGNX) latest ratings:

06/04/2018 Broker: Leerink Swann Rating: Buy New Target: $35.0000 Initiate
14/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $18 New Target: $26 Maintain
05/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $38 Initiates Coverage On
23/01/2018 Broker: SunTrust Rating: Buy New Target: $31.0 Maintain
19/01/2018 Broker: BTIG Research Rating: Buy New Target: $28.0 Maintain
11/12/2017 Broker: Raymond James Rating: Buy
10/11/2017 Broker: Citigroup Rating: Neutral Old Target: $18 New Target: $22 Maintain

Analysts expect Aralez Pharmaceuticals Inc. (TSE:ARZ) to report $-0.32 EPS on May, 8.They anticipate $0.24 EPS change or 42.86% from last quarter’s $-0.56 EPS. After having $-0.48 EPS previously, Aralez Pharmaceuticals Inc.’s analysts see -33.33% EPS growth. It closed at $1.75 lastly. It is down 0.00% since April 25, 2017 and is . It has underperformed by 11.55% the S&P500.

Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical firm in the United States and Canada. The company has market cap of $117.27 million. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It currently has negative earnings. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization.

The stock increased 0.30% or $0.07 during the last trading session, reaching $23.05. About 103,703 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has risen 31.18% since April 25, 2017 and is uptrending. It has outperformed by 19.63% the S&P500.

Since October 25, 2017, it had 0 insider purchases, and 7 insider sales for $1.10 million activity. Wigginton Jon Marc had sold 10,000 shares worth $200,000. 4,000 shares were sold by Risser Eric Blasius, worth $120,000. Shares for $599,436 were sold by Cilinski Lynn. $155,000 worth of MacroGenics, Inc. (NASDAQ:MGNX) was sold by Karrels James on Monday, March 5.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company has market cap of $972.66 million. The companyÂ’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It currently has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

Investors sentiment decreased to 1.11 in 2017 Q4. Its down 0.47, from 1.58 in 2017Q3. It dived, as 14 investors sold MacroGenics, Inc. shares while 31 reduced holdings. 15 funds opened positions while 35 raised stakes. 28.26 million shares or 1.97% more from 27.72 million shares in 2017Q3 were reported. Baker Bros Limited Partnership holds 363,676 shares or 0.06% of its portfolio. Moreover, Citigroup Inc has 0% invested in MacroGenics, Inc. (NASDAQ:MGNX). Principal Gru holds 83,606 shares or 0% of its portfolio. Wasatch Advsr Inc reported 1.03 million shares or 0.26% of all its holdings. Employees Retirement System Of Ohio has 47,715 shares for 0% of their portfolio. 572 were accumulated by Us Bancshares De. Cubist Systematic Strategies Ltd Liability accumulated 0.01% or 6,896 shares. Sphera Funds invested in 0.31% or 138,700 shares. Moreover, Rhumbline Advisers has 0% invested in MacroGenics, Inc. (NASDAQ:MGNX). Amer Group, New York-based fund reported 22,836 shares. Goldman Sachs Gru Inc owns 65,108 shares. Dafna Cap Mngmt Limited owns 1.58% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 154,200 shares. State Street owns 1.05M shares or 0% of their US portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 2,494 shares in its portfolio. Hall Laurie J Trustee accumulated 210 shares.

MacroGenics, Inc. (NASDAQ:MGNX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: